pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
180
stories
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 1, 26
Epigenetic editing shows promise against chronic hep B infections
endpoints
May 28, 26
China gene editing startup YolTech raises $70M to move CRISPR therapies forward
endpoints
May 13, 26
#ASGCT26: After an apparent cure, a gene editing company struggles to repeat the magic
endpoints
May 13, 26
#ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapy
endpoints
May 13, 26
STAT+: Drug meant to make gene therapy safer may also make it less effective
stat
May 13, 26
STAT+: Scientists link boy’s tumor to gene therapy viruses, in rare finding
stat
May 12, 26
STAT+: Capsida says it still doesn’t know what caused gene therapy death
stat
May 11, 26
STAT+: Five years after disaster, a rare disease community gets new chance at treatment
stat
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 5, 26
Vertex earnings get muted investor response
biopharma dive
Apr 29, 26
STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
stat
Apr 29, 26
Chiesi to buy KalVista in $1.9B deal for rare disease drug
biopharma dive
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 29, 26
STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
stat
Apr 28, 26
STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
stat
Apr 28, 26
STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
stat
Apr 28, 26
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
stat
Apr 28, 26
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
stat
Apr 28, 26
Lilly strikes second partnership this year for recombinase-based gene editing
endpoints
Apr 28, 26
STAT+: Eli Lilly enlists AI startup for next-generation gene editors
stat
Apr 27, 26
STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
stat
Apr 27, 26
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next
endpoints
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
Apr 27, 26
STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
stat
Apr 27, 26
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
biopharma dive
Apr 27, 26
Intellia's in vivo CRISPR therapy first to succeed in Phase 3
endpoints
Apr 27, 26
STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
stat
Apr 27, 26
STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
stat
Apr 23, 26
Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
endpoints
← prev
page 6 of 6
next →